No CrossRef data available.
Article contents
Diagnostic testing and antibiotic utilization among inpatients evaluated for coronavirus disease 2019 (COVID-19) pneumonia
Published online by Cambridge University Press: 28 December 2023
Abstract
We evaluated diagnostic test and antibiotic utilization among 252 patients from 11 US hospitals who were evaluated for coronavirus disease 2019 (COVID-19) pneumonia during the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron variant pandemic wave. In our cohort, antibiotic use remained high (62%) among SARS-CoV-2–positive patients and even higher among those who underwent procalcitonin testing (68%).
- Type
- Concise Communication
- Information
- Copyright
- © The Author(s), 2023. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
References
Karaba, SM, Jones, G, Helsel, T, et al. Prevalence of coinfection at time of hospital admission in COVID-19 patients, a multicenter study. Open Forum Infect Dis 2020;8:ofaa578.CrossRefGoogle ScholarPubMed
Langford, BJ, So, M, Raybardhan, S, et al. Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020;26:1622–1629.10.1016/j.cmi.2020.07.016CrossRefGoogle ScholarPubMed
Lansbury, L, Lim, B, Baskaran, V, Lim, WS. Coinfections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;8:266–275.10.1016/j.jinf.2020.05.046CrossRefGoogle Scholar
Learn more about Vizient. Vizient website. https://www.vizientinc.com/about-us. Accessed April 26, 2023.Google Scholar
Metlay, JP, Waterer, GW, Long, AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med 2019;200:e45–e67.CrossRefGoogle ScholarPubMed
Self, WH, Balk, RA, Grijalva, CG, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 2017;65:183–190.CrossRefGoogle ScholarPubMed
Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. Center for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed April 26, 2023.Google Scholar
Fabre, V Karaba, S, Amoah, J, et al. The role of procalcitonin results in antibiotic decision making in coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol 2022;43:570–575.10.1017/ice.2021.175CrossRefGoogle ScholarPubMed
Lippi, G, Plebani, M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chmi Acta 2020;505:190–191.CrossRefGoogle ScholarPubMed